Friedreich's Ataxia

1. Clinical Overview

Summary

Friedreich's ataxia (FRDA) is the most common inherited ataxia in populations of European ancestry, characterized by progressive gait and limb ataxia, sensory neuropathy, and multi-system involvement. [1] It is caused by a GAA trinucleotide repeat expansion in intron 1 of the FXN gene on chromosome 9q21.11, leading to reduced expression of frataxin, a mitochondrial protein essential for iron-sulfur cluster biogenesis and cellular iron homeostasis. [2]

The disease typically manifests before age 25 years (mean onset 10-15 years) with progressive gait ataxia, followed by limb ataxia, dysarthria, sensory loss, and loss of deep tendon reflexes. [3] The pathognomonic neurological finding is the combination of areflexia (lower motor neuron) with extensor plantar responses (upper motor neuron), reflecting the dual pathology of peripheral sensory neuropathy and corticospinal tract degeneration. [4]

Systemic manifestations include hypertrophic cardiomyopathy in over 90% of patients (the leading cause of premature death), diabetes mellitus in 10-40%, skeletal abnormalities (pes cavus, kyphoscoliosis), and visual impairment from optic atrophy. [5,6] Most patients become wheelchair-dependent within 10-15 years of symptom onset, with median survival in the fourth decade of life, though considerable phenotypic variability exists. [7]

Currently, disease management is primarily supportive, focusing on surveillance for cardiac and endocrine complications, multidisciplinary rehabilitation, and management of skeletal deformities. [8] In 2023, omaveloxolone became the first FDA-approved disease-modifying therapy, representing a significant advance in treatment. [9] Gene therapy and other molecular interventions are under active investigation. [10]

Key Facts

Clinical Pearls

"Absent Reflexes + Upgoing Plantars = Friedreich's Until Proven Otherwise": This pathognomonic combination of areflexia (peripheral sensory neuronopathy) with extensor plantar responses (corticospinal tract degeneration) in a young patient with progressive ataxia is virtually diagnostic of FRDA. [4]

"The Heart Kills Before the Brain": While neurological disability defines the clinical course, hypertrophic cardiomyopathy is the leading cause of death, occurring in over 90% of patients. Annual echocardiography and cardiac monitoring are essential. [5,11]

"Pes Cavus + Scoliosis + Ataxia in Adolescence": This triad should immediately prompt consideration of Friedreich's ataxia. The skeletal manifestations often precede or accompany neurological symptoms. [12]

"GAA Repeat Length Predicts Severity": Smaller GAA1 repeats (the shorter of the two alleles) correlate with earlier onset, more severe cardiomyopathy, faster progression, and earlier wheelchair dependency. Repeats >800 are associated with particularly severe phenotypes. [13,14]

"Late-Onset FRDA (LOFA) Is a Different Beast": Patients with onset after age 25 (LOFA) typically have shorter GAA repeats (less than 300), slower progression, milder cardiomyopathy, and better prognosis. Some retain ambulation into their 50s-60s. [15]

"Point Mutations Are Rare but Important": Approximately 4% of patients are compound heterozygotes (GAA expansion + point mutation). These patients may have atypical presentations and require sequencing if GAA testing shows only one expanded allele. [16]

"Idebenone May Protect the Heart": While not curative, idebenone (a synthetic coenzyme Q10 analogue) has shown modest cardiac benefit in some studies, reducing left ventricular hypertrophy in patients with established cardiomyopathy. [17]

Why This Matters Clinically

Friedreich's ataxia represents a devastating multi-system neurodegenerative disorder that profoundly impacts patients and families. Early and accurate diagnosis is critical for several reasons:

1. Cardiac surveillance: Identification of asymptomatic cardiomyopathy allows for early intervention, arrhythmia monitoring, and potentially life-saving treatments. [11]
2. Diabetes screening: Regular endocrine monitoring enables early detection and management of glucose intolerance and diabetes. [6]
3. Genetic counseling: Autosomal recessive inheritance necessitates family counseling, cascade testing, and reproductive planning. [18]
4. Supportive interventions: Early physiotherapy, occupational therapy, and orthopedic management can maximize function and quality of life. [8]
5. Clinical trial access: Accurate molecular diagnosis enables participation in clinical trials of emerging therapies. [10]
6. Prognostic information: Genotype-phenotype correlations allow for more accurate prognostic counseling. [14]

---

2. Epidemiology

Incidence & Prevalence

Age of Onset

Sex Distribution

• Equal sex distribution (autosomal recessive inheritance)
• No sex-linked differences in severity or phenotype

Genetic Epidemiology

---

3. Pathophysiology

Molecular Genetics

The FXN Gene and Frataxin Protein

GAA Trinucleotide Repeat Expansion

Genotype-Phenotype Correlations

GAA1 = length of shorter GAA expansion; primary determinant of phenotype [13,14]

Molecular Pathophysiology

Frataxin Deficiency Cascade

GAA Repeat Expansion (≥66 repeats)
         ↓
Heterochromatin Formation
(H3K9 methylation, HP1 binding)
         ↓
Transcriptional Silencing of FXN
         ↓
Reduced Frataxin mRNA (~25% of normal)
         ↓
Reduced Frataxin Protein (~5-30% of normal)
         ↓
┌────────────────────────────────────────┐
│  IMPAIRED Fe-S CLUSTER BIOGENESIS      │
├────────────────────────────────────────┤
│ • Aconitase deficiency                 │
│ • Complex I/II/III dysfunction         │
│ • Impaired mitochondrial respiration   │
└────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────┐
│  MITOCHONDRIAL IRON ACCUMULATION       │
├────────────────────────────────────────┤
│ • Frataxin normally stores/chaperenes  │
│   iron safely                          │
│ • Deficiency → toxic iron overload     │
└────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────┐
│  OXIDATIVE STRESS                      │
├────────────────────────────────────────┤
│ • Fenton reaction (Fe²⁺ + H₂O₂)       │
│ • Hydroxyl radical generation          │
│ • Lipid peroxidation                   │
│ • Protein oxidation                    │
│ • DNA damage                           │
└────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────┐
│  CELLULAR DYSFUNCTION & DEATH          │
├────────────────────────────────────────┤
│ • Neuronal degeneration                │
│ • Cardiomyocyte dysfunction            │
│ • Beta-cell failure                    │
└────────────────────────────────────────┘

Key Pathophysiological Mechanisms [20]

1. Impaired Fe-S Cluster Biogenesis

   • Fe-S clusters are essential cofactors for electron transport chain complexes I, II, III
   • Aconitase (Fe-S enzyme) deficiency impairs Krebs cycle
   • Multiple metabolic pathways affected

2. Mitochondrial Iron Accumulation

   • Frataxin normally stores iron in a non-toxic form
   • Deficiency → mitochondrial iron overload (especially in heart, DRG neurons)
   • Demonstrable on cardiac MRI (T2* shortening) and tissue staining

3. Oxidative Stress

   • Excess mitochondrial iron catalyzes Fenton reaction
   • Reactive oxygen species (ROS) overwhelm antioxidant defenses
   • Oxidative damage to mitochondrial and cellular components

4. Bioenergetic Failure

   • Impaired ATP production from electron transport chain dysfunction
   • Particularly devastating in high-energy tissues (heart, neurons)

5. Calcium Dysregulation

   • Mitochondrial calcium handling is impaired
   • Contributes to cardiomyocyte dysfunction and arrhythmias

Neuropathology

Macroscopic Changes

Microscopic Pathology

Cardiac Pathophysiology

Hypertrophic Cardiomyopathy Mechanism [5,11]

Pancreatic Pathophysiology

Diabetes Mellitus Mechanism [6]

• Beta-cell dysfunction: Frataxin deficiency impairs insulin secretion
• Oxidative stress: Pancreatic beta cells are particularly vulnerable to ROS
• Progressive beta-cell loss: Results in insulin-dependent diabetes
• Prevalence: 10-40% develop diabetes; 40-80% have glucose intolerance
• Timing: Usually appears after neurological symptoms (mean age 15-20 years)

Skeletal Pathophysiology

• Pes cavus: Results from chronic muscle imbalance (weak intrinsic foot muscles; relatively preserved extrinsics)
• Scoliosis: Likely multifactorial (paraspinal muscle weakness; postural instability; growth during adolescence)
• Progression: Often requires surgical intervention in severe cases

---

4. Clinical Presentation

Typical Presentation Timeline

Neurological Features

Motor System

Reflexes

Sensory System

Cerebellar Signs

Cardiac Features [5,11]

Endocrine Features [6]

Skeletal Features [12]

Ophthalmological Features [21]

Other Systemic Features

---

5. Clinical Examination

Systematic Neurological Examination

Inspection

Gait Assessment

Upper Limb Examination

Lower Limb Examination

Sensory Examination

Cranial Nerve Examination

Cardiac Examination

Musculoskeletal Examination

Comprehensive Examination Checklist for FRDA

• Observe gait (ataxic, wide-based)
• Romberg test (positive)
• Cerebellar signs (dysmetria, dysdiadochokinesis, intention tremor)
• Absent deep tendon reflexes (especially lower limbs)
• Extensor plantar responses (Babinski sign)
• Vibration and proprioception loss
• Dysarthria (cerebellar pattern)
• Pes cavus examination
• Scoliosis assessment
• Cardiac examination (LVH, murmur, heart failure signs)
• Visual acuity and optic disc examination
• Assess functional status (ambulation, wheelchair use, ADLs)

---

6. Differential Diagnosis

Key Differentials for Progressive Ataxia in Young Patients

Specific Diagnostic Challenges

Vitamin E Deficiency (AVED) - The Great Mimicker

• Clinical phenocopy: Virtually identical to FRDA (ataxia, areflexia, Babinski, pes cavus)
• Key difference: AVED is treatable with high-dose vitamin E supplementation
• Investigation: Measure serum vitamin E; screen for TTPA gene mutations
• Importance: Always exclude AVED before diagnosing FRDA

Late-Onset Friedreich's Ataxia (LOFA) vs. Other Adult-Onset Ataxias

---

7. Investigations

Diagnostic Algorithm

Clinical Suspicion (Progressive ataxia + absent reflexes + Babinski)
                        ↓
┌─────────────────────────────────────────────────────────┐
│          FIRST-LINE GENETIC TESTING                     │
├─────────────────────────────────────────────────────────┤
│  FXN Gene GAA Repeat Analysis                          │
│                                                         │
│  ≥66 repeats in BOTH alleles → DIAGNOSIS CONFIRMED     │
│                                                         │
│  One expanded allele only → Proceed to FXN sequencing  │
│  (suspect compound heterozygote with point mutation)   │
│                                                         │
│  No expansion → Consider differential diagnoses         │
└─────────────────────────────────────────────────────────┘
                        ↓
┌─────────────────────────────────────────────────────────┐
│         EXCLUDE TREATABLE MIMICS                        │
├─────────────────────────────────────────────────────────┤
│  • Serum Vitamin E (exclude AVED)                      │
│  • Lipid profile (exclude abetalipoproteinemia)        │
│  • Serum ceruloplasmin (exclude Wilson disease)        │
└─────────────────────────────────────────────────────────┘
                        ↓
┌─────────────────────────────────────────────────────────┐
│        BASELINE MULTI-SYSTEM ASSESSMENT                 │
├─────────────────────────────────────────────────────────┤
│  CARDIAC:                                               │
│  • ECG                                                  │
│  • Echocardiography                                     │
│  • Consider cardiac MRI (assess fibrosis, iron)        │
│                                                         │
│  ENDOCRINE:                                             │
│  • Fasting glucose and/or HbA1c                        │
│  • Oral glucose tolerance test (if borderline)         │
│                                                         │
│  NEUROPHYSIOLOGY:                                       │
│  • Nerve conduction studies (sensory axonal neuropathy)│
│  • Somatosensory evoked potentials (absent/delayed)    │
│                                                         │
│  NEUROIMAGING:                                          │
│  • MRI brain and cervical spine (exclude structural)   │
│  • Spinal cord atrophy (supportive finding)            │
│                                                         │
│  ORTHOPEDIC:                                            │
│  • Spine X-rays (scoliosis assessment and monitoring)  │
│  • Foot X-rays if surgical correction considered       │
│                                                         │
│  OPHTHALMOLOGY:                                         │
│  • Visual acuity, fundoscopy (optic atrophy)           │
└─────────────────────────────────────────────────────────┘

Genetic Testing [2,16]

Interpretation of GAA Repeat Length:

Cardiac Investigations [5,11]

Echocardiographic Monitoring Schedule:

• Baseline at diagnosis
• Annual thereafter
• More frequent if abnormalities detected or symptoms develop

Endocrine Investigations [6]

Neurophysiology

Neuroimaging

Other Investigations

Biomarkers (Research/Emerging)

---

8. Management

Principles of Care

Friedreich's ataxia currently has no curative treatment. Management is primarily supportive and preventative, focusing on:

1. Surveillance for cardiac and endocrine complications
2. Multidisciplinary rehabilitation to maximize function and quality of life
3. Management of complications (heart failure, diabetes, skeletal deformities)
4. Disease-modifying therapy (omaveloxolone - FDA approved 2023)
5. Genetic counseling and family support
6. Clinical trial participation when appropriate

Comprehensive Management Algorithm

FRIEDREICH'S ATAXIA: MULTIDISCIPLINARY MANAGEMENT PATHWAY
═══════════════════════════════════════════════════════════

┌────────────────────────────────────────────────────────┐
│  1. DIAGNOSIS & GENETIC COUNSELING                     │
├────────────────────────────────────────────────────────┤
│  ✓ Genetic confirmation (FXN GAA repeat analysis)     │
│  ✓ Provide diagnosis sensitively (incurable, life-    │
│    limiting condition)                                 │
│  ✓ Genetic counseling for patient and family          │
│  ✓ Cascade testing of at-risk relatives (carriers)    │
│  ✓ Reproductive counseling (prenatal/PGD options)     │
│  ✓ Connect with patient organizations (FARA, Ataxia   │
│    UK)                                                 │
│  ✓ Discuss prognosis honestly (variable; median       │
│    survival 35-40 years)                               │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  2. CARDIAC SURVEILLANCE & MANAGEMENT                  │
│     ⚠️ LEADING CAUSE OF DEATH - MOST CRITICAL          │
├────────────────────────────────────────────────────────┤
│  SURVEILLANCE:                                         │
│  • Annual echocardiography (mandatory) [11]           │
│  • Annual ECG                                          │
│  • 24-hour Holter if symptoms (palpitations, syncope) │
│  • Cardiac MRI if echo inadequate or fibrosis         │
│    assessment needed                                   │
│                                                        │
│  HYPERTROPHIC CARDIOMYOPATHY MANAGEMENT:               │
│  • ACE inhibitors or ARBs (LV remodeling, heart       │
│    failure) [11]                                       │
│  • Beta-blockers (symptomatic HOCM, arrhythmia)       │
│  • Avoid dehydration, extreme exertion                │
│  • Diuretics for heart failure symptoms               │
│                                                        │
│  ARRHYTHMIA MANAGEMENT:                                │
│  • Antiarrhythmics (amiodarone, sotalol) as indicated│
│  • Anticoagulation for atrial fibrillation            │
│  • ICD consideration (primary/secondary prevention of  │
│    sudden cardiac death) - individualized [11]        │
│                                                        │
│  ADVANCED HEART FAILURE:                               │
│  • Cardiology/heart failure specialist referral       │
│  • Heart transplant evaluation (rare; case reports)   │
│                                                        │
│  ⚠️ RED FLAGS (urgent cardiology):                     │
│    - Syncope, presyncope                               │
│    - Chest pain, palpitations                         │
│    - New dyspnea, orthopnea, PND                      │
│    - Worsening LV function on echo                    │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  3. ENDOCRINE SURVEILLANCE & MANAGEMENT                │
├────────────────────────────────────────────────────────┤
│  SURVEILLANCE:                                         │
│  • Annual fasting glucose or HbA1c [6]                │
│  • OGTT if borderline glucose                         │
│                                                        │
│  DIABETES MANAGEMENT:                                  │
│  • Standard diabetes guidelines                       │
│  • Often requires insulin (beta-cell failure)         │
│  • Diabetic retinopathy, nephropathy screening        │
│  • Multidisciplinary diabetes team                    │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  4. DISEASE-MODIFYING PHARMACOTHERAPY                  │
├────────────────────────────────────────────────────────┤
│  OMAVELOXOLONE (FDA-approved Feb 2023) [9]:           │
│  • Indication: Friedreich's ataxia (age ≥16 years)    │
│  • Mechanism: Nrf2 pathway activator (antioxidant     │
│    response; mitochondrial biogenesis)                │
│  • Dose: 150 mg once daily (oral; with/without food)  │
│  • Evidence: MOXIe trial showed improvement in mFARS  │
│    (modified Friedreich's Ataxia Rating Scale) vs     │
│    placebo [9]                                         │
│  • Effect size: Modest but significant; slows         │
│    progression                                         │
│  • Adverse effects: Elevated liver enzymes (monitor   │
│    LFTs); headache; nausea; fatigue                   │
│  • Monitoring: LFTs at baseline, 1, 3, 6 months, then │
│    every 6 months                                      │
│  • Cost: High; insurance/access variable by region   │
│                                                        │
│  IDEBENONE (off-label; mixed evidence) [17]:          │
│  • Synthetic CoQ10 analogue; antioxidant              │
│  • Dose: 900-2250 mg/day (divided doses)              │
│  • Evidence: NICOSIA trial showed cardiac benefit     │
│    (reduced LVH in subset with baseline               │
│    hypertrophy); neurological benefit unclear [17]    │
│  • Consider: Patients with established cardiomyopathy │
│    (consult cardiology)                               │
│  • Availability: Not FDA-approved for FRDA; available │
│    in Europe                                           │
│                                                        │
│  OTHER ANTIOXIDANTS (insufficient evidence):          │
│  • Vitamin E, CoQ10: No proven benefit; not           │
│    recommended routinely                              │
│  • EPI-743 (vatiquinone): Clinical trials ongoing    │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  5. NEUROLOGICAL REHABILITATION [8]                    │
├────────────────────────────────────────────────────────┤
│  PHYSIOTHERAPY:                                        │
│  ✓ Balance and coordination training                  │
│  ✓ Gait re-education                                  │
│  ✓ Stretching and range-of-motion exercises (prevent  │
│    contractures)                                       │
│  ✓ Strengthening (within functional capacity)         │
│  ✓ Hydrotherapy (well-tolerated)                      │
│  ✓ Assistive devices:                                 │
│    - Walking aids (cane, walker) as needed            │
│    - Wheelchair prescription (manual → powered)       │
│  ✓ Falls prevention strategies                        │
│                                                        │
│  OCCUPATIONAL THERAPY:                                 │
│  ✓ ADL assessment and training                        │
│  ✓ Home environment modification (rails, ramps, etc.) │
│  ✓ Adaptive equipment (dressing, feeding aids)        │
│  ✓ Wheelchair seating and positioning                 │
│  ✓ Vocational assessment and support                  │
│  ✓ Driving assessment (often unsafe once moderate     │
│    ataxia)                                             │
│                                                        │
│  SPEECH AND LANGUAGE THERAPY:                          │
│  ✓ Dysarthria management (speech exercises, pacing)   │
│  ✓ Communication aids (augmentative devices in severe │
│    dysarthria)                                         │
│  ✓ Swallowing assessment (videofluoroscopy if         │
│    dysphagia)                                          │
│  ✓ Dietary modification (texture, consistency)        │
│  ✓ Feeding tube consideration (PEG) if severe         │
│    dysphagia/aspiration                               │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  6. ORTHOPEDIC MANAGEMENT [12]                         │
├────────────────────────────────────────────────────────┤
│  SCOLIOSIS:                                            │
│  • Serial X-rays to monitor progression (6-12 monthly │
│    in adolescence)                                     │
│  • Bracing (thoracolumbosacral orthosis) if Cobb angle│
│    25-40 degrees and still growing                    │
│  • Spinal fusion surgery if:                          │
│    - Cobb angle >40-50 degrees                        │
│    - Progressive despite bracing                      │
│    - Respiratory compromise                           │
│    - Seating/balance difficulties                     │
│  • Risks of surgery: Cardiac anesthesia risk; healing │
│    complications                                       │
│  • Benefits: Improved seating, respiratory function,  │
│    pain reduction                                      │
│                                                        │
│  PES CAVUS:                                            │
│  • Orthotic insoles (cushioning, arch support)        │
│  • Ankle-foot orthoses (AFOs) if footdrop             │
│  • Surgical correction (calcaneal osteotomy, plantar  │
│    fascia release) in selected cases                  │
│                                                        │
│  CONTRACTURES:                                         │
│  • Regular stretching (PT essential)                  │
│  • Serial casting if severe                           │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  7. ADDITIONAL SUPPORTIVE CARE                         │
├────────────────────────────────────────────────────────┤
│  OPHTHALMOLOGY:                                        │
│  • Baseline eye exam                                  │
│  • Visual acuity monitoring if optic atrophy          │
│  • Low vision aids if visual impairment               │
│  • Diabetic retinopathy screening (if diabetic)       │
│                                                        │
│  AUDIOLOGY:                                            │
│  • Hearing assessment (high-frequency loss common)    │
│  • Hearing aids if significant loss                   │
│                                                        │
│  RESPIRATORY:                                          │
│  • Pulmonary function tests (baseline, serial if      │
│    severe scoliosis)                                   │
│  • Respiratory physiotherapy (incentive spirometry,   │
│    assisted cough)                                     │
│  • NIV (non-invasive ventilation) in late-stage       │
│    respiratory failure (rare)                         │
│  • Pneumococcal/influenza vaccination                 │
│                                                        │
│  NUTRITION:                                            │
│  • Nutritional assessment (swallowing difficulties,   │
│    weight loss)                                        │
│  • Dietitian input (high-calorie diet if wasting;     │
│    diabetic diet if DM)                               │
│  • PEG feeding tube if severe dysphagia/aspiration    │
│                                                        │
│  PSYCHOLOGY/PSYCHIATRY:                                │
│  • Screen for depression, anxiety (common)            │
│  • Psychological support, counseling                  │
│  • Antidepressants if indicated                       │
│  • Peer support groups                                │
│                                                        │
│  PAIN MANAGEMENT:                                      │
│  • Musculoskeletal pain common (scoliosis, gait       │
│    abnormalities)                                      │
│  • Analgesics, muscle relaxants as needed             │
│                                                        │
│  PALLIATIVE CARE:                                      │
│  • Early integration for symptom management, advance  │
│    care planning                                       │
│  • End-of-life care planning (discuss resuscitation,  │
│    ventilation wishes)                                │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  8. CLINICAL TRIALS & EMERGING THERAPIES [10]          │
├────────────────────────────────────────────────────────┤
│  GENE THERAPY:                                         │
│  • Viral vector-mediated frataxin gene replacement    │
│  • Phase I/II trials ongoing                          │
│  • AAV-based delivery to CNS and/or systemic          │
│                                                        │
│  FRATAXIN REPLACEMENT:                                 │
│  • Recombinant frataxin protein (delivery challenge)  │
│  • Protein transduction approaches                    │
│                                                        │
│  GENE EDITING:                                         │
│  • CRISPR-based approaches to reactivate FXN gene     │
│  • Preclinical development                            │
│                                                        │
│  INTERFERON GAMMA:                                     │
│  • Increases frataxin expression in vitro             │
│  • Clinical trials showed modest frataxin increase;   │
│    unclear clinical benefit                           │
│                                                        │
│  HDAC INHIBITORS:                                      │
│  • Epigenetic modulation to increase FXN expression   │
│  • Nicotinamide, RG2833 in trials                     │
│                                                        │
│  OTHER NEUROPROTECTIVE AGENTS:                         │
│  • Erythropoietin                                     │
│  • Deferiprone (iron chelator - mixed results)       │
│  • EPI-743 (vatiquinone)                              │
│                                                        │
│  ✓ Encourage trial participation where eligible       │
│  ✓ Check clinicaltrials.gov, FARA website             │
└────────────────────────────────────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────────┐
│  9. SURVEILLANCE SCHEDULE                              │
├────────────────────────────────────────────────────────┤
│  ANNUAL ASSESSMENTS:                                   │
│  ✓ Cardiology review + echocardiography + ECG [11]   │
│  ✓ Endocrine screen (glucose/HbA1c) [6]               │
│  ✓ Neurology review (functional assessment, mFARS)    │
│  ✓ PT/OT assessment                                   │
│  ✓ Spine X-ray (if adolescent/progressive scoliosis)  │
│                                                        │
│  AS INDICATED:                                         │
│  • Holter monitor (if palpitations, syncope)          │
│  • Cardiac MRI (if echo inadequate, fibrosis          │
│    assessment)                                         │
│  • Pulmonary function tests (if severe scoliosis)     │
│  • Swallowing assessment (if dysphagia)               │
│  • Ophthalmology (if visual symptoms)                 │
│  • Audiology (if hearing loss)                        │
└────────────────────────────────────────────────────────┘

Pharmacological Summary Table

Interventional Cardiology

What NOT to Do

---

9. Complications

Cardiac Complications [5,11]

Endocrine Complications [6]

Neurological Complications

Orthopedic Complications [12]

Respiratory Complications

Psychosocial Complications

Iatrogenic/Procedure Complications

---

10. Prognosis & Outcomes

Natural History

Survival and Mortality [7]

Prognostic Factors

Age of Onset [13,14,15]

GAA Repeat Length [13,14]

GAA1 length is the primary genetic determinant of age of onset and disease severity

Cardiac Phenotype [11]

Other Prognostic Factors

Functional Outcomes

Quality of Life

• Physical QoL: Severely impaired by disability, cardiac symptoms, pain
• Psychological QoL: High rates of depression, anxiety; social isolation
• Interventions improve QoL: Multidisciplinary care; psychological support; peer support groups
• Omaveloxolone impact: Modest functional benefit; long-term QoL impact under study [9]

Survival Curves (Approximate)

• 10-year survival from onset: ~95%
• 20-year survival: ~70-80%
• 30-year survival: ~40-50%
• 40-year survival: ~20-30%

(Wide variability based on age of onset and GAA repeat length)

---

11. Evidence & Guidelines

Key Clinical Trials

Clinical Practice Guidelines

Consensus Recommendations

1. Annual cardiac surveillance with echocardiography is essential (leading cause of death) [11]
2. Annual diabetes screening (fasting glucose or HbA1c) [6]
3. Multidisciplinary rehabilitation improves functional outcomes and quality of life [8]
4. Genetic counseling should be offered to all patients and families [18]
5. Omaveloxolone should be considered in eligible patients (age ≥16, FDA-approved) [9]
6. Scoliosis monitoring in adolescents; surgical intervention if severe and progressive [12]

Evidence Gaps and Ongoing Research [10]

• Gene therapy: Viral vector-mediated FXN gene replacement (Phase I/II trials)
• Frataxin replacement: Recombinant protein delivery strategies
• Epigenetic modulation: HDAC inhibitors, DNA methylation inhibitors to increase FXN expression
• CRISPR gene editing: Reactivate silenced FXN gene
• Cardiac-specific therapies: Novel HCM treatments applicable to FRDA
• Biomarkers: Frataxin protein levels, neurofilament light chain for disease monitoring
• Outcome measures: Development of sensitive, clinically meaningful endpoints for trials

---

12. Patient & Family Information

What is Friedreich's Ataxia?

Friedreich's ataxia is an inherited condition that affects the nervous system, heart, and other parts of the body. It causes problems with balance, coordination, and movement that get worse over time. It also affects the heart and can cause diabetes.

What Causes It?

Friedreich's ataxia is caused by a change (mutation) in a gene called FXN. This gene provides instructions for making a protein called frataxin, which is important for the energy-producing parts of cells (mitochondria). When there isn't enough frataxin, cells—especially in the nervous system and heart—don't work properly and can be damaged.

The condition is inherited in an autosomal recessive pattern, which means:

• Both parents are "carriers" (they have one changed gene but are healthy)
• There is a 25% (1 in 4) chance with each pregnancy that a child will have Friedreich's ataxia
• There is a 50% chance the child will be a carrier
• There is a 25% chance the child will not be affected and not be a carrier

What Are the Symptoms?

Symptoms usually start in the teenage years (around 10-15 years old), but can begin earlier or later. Common symptoms include:

Neurological (nervous system):

• Difficulty walking and balance problems (usually the first symptom)
• Clumsiness and frequent falls
• Slurred speech
• Loss of feeling in the feet and hands
• Muscle weakness (later in the disease)

Other body systems:

• Heart problems (almost everyone with Friedreich's ataxia develops a thickened heart muscle)
• Diabetes (affects 10-40% of people)
• Curved spine (scoliosis) - very common
• High-arched feet (pes cavus) - very common
• Vision and hearing problems (in some people)

How is it Diagnosed?

Diagnosis is made by:

1. Clinical examination: A doctor will assess balance, reflexes, and coordination
2. Genetic testing: A blood test can identify the mutation in the FXN gene (this confirms the diagnosis)
3. Heart tests: ECG and echocardiogram (ultrasound of the heart) to check for heart problems
4. Other tests: Blood sugar tests; spine X-rays; nerve tests

What is the Outlook?

Friedreich's ataxia is a progressive condition, meaning it gets worse over time. The rate of progression varies from person to person.

• Most people need a wheelchair within 10-15 years of symptoms starting
• Life expectancy is reduced; many people live into their 30s and 40s, though some live longer
• Heart problems are the most common cause of death

Important: The disease progresses differently in each person. Some people have milder symptoms and slower progression, especially if symptoms start later in life.

How is it Treated?

There is currently no cure for Friedreich's ataxia, but there are treatments to help manage symptoms and slow progression:

New medication (2023):

• Omaveloxolone (Skyclarys®): The first FDA-approved drug for Friedreich's ataxia. It can slow the progression of symptoms in some people.

Heart care:

• Regular heart check-ups (echocardiograms) every year
• Medications to help the heart work better if needed
• Sometimes devices like pacemakers or defibrillators

Diabetes care:

• Regular blood sugar monitoring
• Diabetes medications or insulin if needed

Physical and supportive therapy:

• Physiotherapy: Exercises to maintain strength and balance
• Occupational therapy: Help with daily activities and home adaptations
• Speech therapy: Help with speech and swallowing problems
• Walking aids and wheelchairs: To help with mobility
• Orthopedic care: Braces or surgery for scoliosis if needed

Mental health support:

• Counseling and support for depression and anxiety (very common)
• Support groups to connect with others with Friedreich's ataxia

What About My Family?

If you or your child has Friedreich's ataxia:

• Siblings: Brothers and sisters have a 25% chance of also having the condition and should be tested
• Parents: Both parents are carriers; genetic counseling can help with family planning
• Your children: If you have Friedreich's ataxia, your children will be carriers unless your partner is also a carrier (rare)
• Prenatal testing: Available if there is a known risk in the family
• Preimplantation genetic diagnosis: Available with IVF to prevent passing on the condition

Where Can I Get Support?

Patient Organizations:

• Friedreich's Ataxia Research Alliance (FARA): www.curefa.org (USA)
• Ataxia UK: www.ataxia.org.uk (UK)
• National Ataxia Foundation: www.ataxia.org (USA)
• EURO-ATAXIA: www.ataxia-europe.org (Europe)

These organizations provide:

• Information about the condition
• Connection with other families
• Updates on research and clinical trials
• Fundraising and advocacy

Questions to Ask Your Doctor

1. What is the likely progression of the disease in my case?
2. Am I eligible for omaveloxolone treatment?
3. How often do I need heart check-ups?
4. What therapies are available to help me maintain function?
5. Are there clinical trials I can participate in?
6. What support is available for my family?
7. How can I plan for the future (work, education, care needs)?

---

13. Examination Focus (MRCP, FRACP, Medical Postgraduate Exams)

High-Yield Exam Topics

Classic Examination Scenarios

PACES Station 3 (Cardiovascular and Neurological) - Classic Case

Scenario: "This 22-year-old patient has difficulty walking. Please examine the neurological system in the lower limbs."

Expected Findings:

• Wide-based ataxic gait
• Pes cavus (high-arched feet)
• Positive Romberg test
• Absent ankle and knee reflexes
• Extensor plantar responses bilaterally
• Reduced vibration and proprioception
• Mild lower limb weakness (variable)
• Kyphoscoliosis (if examined standing)

Diagnosis: "This patient has the classic signs of Friedreich's ataxia: the combination of areflexia and extensor plantar responses, along with ataxia, pes cavus, and scoliosis."

Follow-up Questions:

• What is the genetic basis? (AR; GAA repeat in FXN gene; frataxin deficiency)
• What are the systemic features? (HOCM, diabetes, skeletal deformities)
• How would you investigate? (Genetic testing; exclude vitamin E deficiency; echo; glucose)
• What is the leading cause of death? (Cardiac - cardiomyopathy, arrhythmia, heart failure)
• How would you manage? (Annual cardiac surveillance; diabetes screening; multidisciplinary rehab; omaveloxolone; genetic counseling)

Written Exam SBA (Single Best Answer)

Question 1: A 16-year-old girl presents with a 2-year history of progressive difficulty walking and frequent falls. Examination reveals ataxic gait, absent knee and ankle reflexes, and bilateral extensor plantar responses. She has high-arched feet. What is the most likely diagnosis?

A. Multiple sclerosis B. Friedreich's ataxia C. Spinocerebellar ataxia type 1 D. Vitamin B12 deficiency E. Hereditary spastic paraplegia

Answer: B. Friedreich's ataxia

The combination of areflexia and extensor plantars is pathognomonic for Friedreich's ataxia, along with ataxia and pes cavus in a young patient.

---

Question 2: A 14-year-old boy is diagnosed with Friedreich's ataxia following genetic testing. Which of the following is the most important surveillance investigation?

A. Annual MRI brain B. Annual pulmonary function tests C. Annual echocardiography D. Six-monthly nerve conduction studies E. Annual EMG

Answer: C. Annual echocardiography

Hypertrophic cardiomyopathy is the leading cause of death in Friedreich's ataxia and requires annual surveillance. Early detection allows for management of heart failure and arrhythmias.

---

Question 3: Which of the following is a treatable condition that can mimic Friedreich's ataxia and must be excluded?

A. Spinocerebellar ataxia type 3 B. Ataxia-telangiectasia C. Vitamin E deficiency (AVED) D. Multiple sclerosis E. Refsum disease

Answer: C. Vitamin E deficiency (AVED)

AVED is a phenocopy of Friedreich's ataxia but is treatable with high-dose vitamin E supplementation. Serum vitamin E must be checked in all patients presenting with a Friedreich-like phenotype.

Viva Voce Scenario

Examiner: "A 15-year-old boy presents with a 1-year history of progressive gait difficulty and clumsiness. On examination, he has an ataxic gait, pes cavus, absent knee and ankle reflexes, and upgoing plantars. What is your differential diagnosis and how would you investigate?"

Model Answer:

"The combination of absent reflexes with extensor plantar responses in a young patient with progressive ataxia is highly suggestive of Friedreich's ataxia. This mixed upper and lower motor neuron picture reflects the dual pathology of peripheral sensory neuronopathy (dorsal root ganglia degeneration causing areflexia) and corticospinal tract involvement (causing upgoing plantars).

Differential diagnosis includes:

1. Friedreich's ataxia (most likely)
2. Vitamin E deficiency (AVED) - treatable phenocopy
3. Abetalipoproteinemia (if young child with fat malabsorption)
4. Other inherited ataxias (less likely with this reflex pattern)

Investigations:

Genetic:

• FXN gene GAA repeat analysis (diagnostic for Friedreich's ataxia)

Exclude treatable mimics:

• Serum vitamin E (exclude AVED - this is critical as it's treatable)
• Lipid profile (exclude abetalipoproteinemia)

Baseline multi-system assessment:

• Cardiac: ECG and echocardiography (>90% have hypertrophic cardiomyopathy; leading cause of death)
• Endocrine: Fasting glucose or HbA1c (screen for diabetes)
• Neurophysiology: Nerve conduction studies (sensory axonal neuropathy)
• Imaging: MRI brain and cervical spine (exclude structural causes; may show cord atrophy)
• Skeletal: Spine X-rays (assess scoliosis)

Management:

• Genetic counseling (autosomal recessive; family implications)
• Annual cardiac surveillance (echocardiography - most important for preventing cardiac death)
• Annual diabetes screening
• Multidisciplinary approach: physiotherapy, occupational therapy, speech therapy
• Omaveloxolone (FDA-approved disease-modifying therapy)
• Idebenone (off-label cardiac benefit)
• Scoliosis monitoring and orthopedic management
• Psychological support (depression common)
• Clinical trial consideration

Prognosis: Progressive neurological disability with wheelchair dependency typically within 10-15 years of symptom onset. Median survival is 35-40 years, with cardiac complications being the leading cause of death."

---

Examiner Follow-up: "What is the genetic mechanism, and how does it relate to disease severity?"

Model Answer:

"Friedreich's ataxia is caused by a GAA trinucleotide repeat expansion in intron 1 of the FXN gene on chromosome 9q21.11, inherited in an autosomal recessive pattern. Normal individuals have 5-33 GAA repeats, whereas affected individuals have ≥66 repeats (typically 600-900).

The expanded GAA repeat forms abnormal DNA structures that lead to heterochromatin formation and transcriptional silencing, resulting in severely reduced frataxin mRNA and protein (5-30% of normal levels).

Frataxin is a mitochondrial matrix protein essential for iron-sulfur cluster biogenesis. Deficiency leads to:

1. Impaired mitochondrial respiration
2. Mitochondrial iron accumulation
3. Oxidative stress and cell damage
4. Particularly affects high-energy tissues: nervous system (DRG, spinocerebellar tracts, corticospinal tracts) and heart

Genotype-phenotype correlation:

• The length of the shorter GAA repeat (GAA1) is the primary determinant of disease severity
• Larger GAA1 (>800 repeats): earlier onset (less than 10 years), severe cardiomyopathy, rapid progression
• Smaller GAA1 (less than 300 repeats): late-onset Friedreich's ataxia (LOFA) with onset >25 years, slower progression, milder cardiac involvement, better prognosis

Approximately 4% of patients are compound heterozygotes (one GAA expansion + one point mutation), which can result in atypical presentations."

---

Must-Know Facts for Exams

1. Pathognomonic sign: Areflexia + extensor plantars (LMN + UMN)
2. Most common inherited ataxia in European populations
3. Autosomal recessive; GAA trinucleotide repeat in FXN gene
4. Frataxin deficiency → mitochondrial dysfunction → oxidative stress
5. Typical onset: 10-15 years (puberty)
6. Pes cavus and kyphoscoliosis are nearly universal
7. Hypertrophic cardiomyopathy in >90%; leading cause of death
8. Annual echocardiography is mandatory surveillance
9. Diabetes mellitus in 10-40%
10. Vitamin E deficiency (AVED) is a treatable mimic - must exclude
11. Omaveloxolone (2023) is first FDA-approved disease-modifying therapy
12. Wheelchair dependency typically 10-15 years from onset
13. Median survival 35-40 years
14. GAA1 repeat length predicts severity (shorter repeat = milder disease)
15. No cure; management is supportive + surveillance + omaveloxolone

---

14. References

1. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256 Suppl 1:3-8. doi:10.1007/s00415-009-1002-3 PMID: 19283344

2. Campuzano V, Montermini L, Moltò MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423-1427. PMID: 8596916

3. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104(3):589-620. PMID: 7272714

4. Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72(2):78-90. doi:10.1097/NEN.0b013e31827e5762 PMID: 23334592

5. Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1-2):46-49. doi:10.1016/j.jns.2011.05.023 PMID: 21652007

6. Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem. 2013;126 Suppl 1:94-102. doi:10.1111/jnc.12216 PMID: 23859345

7. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996;335(16):1169-1175. PMID: 8815938

8. Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR. Friedreich ataxia: clinical features and new developments. Neurodegener Dis Manag. 2022;12(5):267-283. doi:10.2217/nmt-2022-0011 PMID: 36111390

9. Lynch DR, Chin MP, Delatycki MB, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021;89(2):212-225. doi:10.1002/ana.25934 PMID: 33131110

10. Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J Neurochem. 2013;126 Suppl 1:103-117. doi:10.1111/jnc.12317 PMID: 23859346

11. Weidemann F, Rummey C, Bijnens B, et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation. 2012;125(13):1626-1634. doi:10.1161/CIRCULATIONAHA.111.059501 PMID: 22379112

12. Delatycki MB, Holian A, Corben L, et al. Surgery for equinovarus deformity in Friedreich's ataxia improves mobility and independence. Clin Orthop Relat Res. 2005;430:138-141. PMID: 15662316

13. Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996;59(3):554-560. PMID: 8751856

14. Monticelli A, Gillis T, Hasan M, et al. Relationship between expanded GAA repeat length and age at symptom onset in Friedreich ataxia. Mov Disord. 2004;19(2):247-252. doi:10.1002/mds.10659 PMID: 14978688

15. De Michele G, Perrone F, Filla A, et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients. Neurology. 1996;47(5):1260-1264. PMID: 8909440

16. Cossée M, Dürr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. 1999;45(2):200-206. PMID: 9989622

17. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;259(2):284-291. doi:10.1007/s00415-011-6174-y PMID: 21779958

18. Delatycki MB, Paris DB, Gardner RJ, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999;87(2):168-174. PMID: 10533032

19. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006;2(10):551-558. PMID: 16921367

20. Palomo GM, Cerrato T, Gargini R, Diaz-Nido J. Silencing of frataxin gene expression triggers p53-dependent apoptosis in human neuron-like cells. Hum Mol Genet. 2011;20(14):2807-2822. doi:10.1093/hmg/ddr187 PMID: 21536587

21. Fortuna F, Barboni P, Liguori R, et al. Visual system involvement in patients with Friedreich's ataxia. Brain. 2009;132(Pt 1):116-123. doi:10.1093/brain/awn269 PMID: 18931390

22. Pandolfo M, Arpa J, Delatycki MB, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014;76(4):509-521. doi:10.1002/ana.24248 PMID: 25112863

---

Last Reviewed: 2026-01-08 | MedVellum Editorial Team Citation Count: 22 Evidence Level: High